Recent Updates
Recently added Catalysts
NOTV

FOR MORE INFORMATION: Michael R Cox Phone 765.497.5829 mcox@bioanalytical.com Bioanalytical Systems, Inc. Issues Revised Fourth Quarter and Year-End 2005 Financial Results

Key Takeaway: Bioanalytical Systems, Inc. Issues Revised Fourth Quarter and Year-End 2005 Financial Results WEST LAFAYETTE, Ind., January 16, 2006 -- Bioanalytical Systems, Inc. (Nasdaq: BASI) today issued revised financial results for its fourth quarter and fiscal year ended September 30, 20

Full Press Release Details

Bioanalytical Systems, Inc. Issues Revised Fourth Quarter and Year-End 2005 Financial Results
WEST LAFAYETTE, Ind., January 16, 2006 -- Bioanalytical Systems, Inc. (Nasdaq: BASI) today issued revised financial results for its fourth quarter and fiscal year ended September 30, 2005. The revision was necessary as a result of adjustments at the Company s foreign subsidiaries. These adjustments resulted in decreasing revenues by $37,000 and increasing cost of revenue by $22,000. General and administrative expenses were increased by $25,000, and income taxes were increased by $22,000. As a result, net results of operations for the quarter and fiscal year ended September 30, 2005 were reduced by $106,000. Revised net earnings for the quarter were $36,000 ($0.01 per share) compared to previously announced net earnings of $142,000 ($0.03 per share). For the fiscal year, results of operations were revised to a loss of $101,000 (loss of $0.02 per share) from a profit of $5,000 ($0.00 per share).
The Company s revised quarterly and fiscal year end results for the periods ended September 30, 2005 are attached.
About Bioanalytical Systems, Inc.
BASi is a pharmaceutical development company providing contract research services and monitoring instruments to the world s leading drug development companies and medical research organizations. The company focuses on developing innovative services and products that increase efficiency and reduce the cost of taking a new drug to market. Visit http://www.bioanalytical.com for more about BASi.
This release contains forward-looking statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties
related to the development of products and services, changes in technology, industry standards and regulatory standards, and various market
and operating risks detailed in the company s filings with the Securities and Exchange Commission.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
Three Months Ended September 30, Years Ended September 30,
2005 2004 2005 2004
Service revenue $ 9,041,000 $ 5,658,000 $ 32,951,000 $ 24,928,000
Product revenue 3,218,000 3,436,000 9,444,000 12,224,000
Total revenue 12,259,000 9,094,000 42,395,000 37,152,000
Cost of service revenue 7,019,000 5,854,000 23,589,000 21,348,000
Cost of product revenue 1,110,000 768,000 3,462,000 4,270,000
Total cost of revenue 8,129,000 6,622,000 27,051,000 25,618,000
Gross profit 4,130,000 2,472,000 15,344,000 11,534,000
Operating expenses:
Selling 673,000 740,000 2,592,000 2,703,000
Research and development 673,000 299,000 1,326,000 1,100,000
General and administrative 2,407,000 1,792,000 10,188,000 7,477,000
Total operating expenses 3,753,000 2,831,000 14,106,000 11,280,000
Operating income (loss) 377,000 (359,000 ) 1,238,000 254,000
Other income (expense) (55,000 ) 64,000 1,000 103,000
Interest income 12,000 3,000 19,000 8,000
Interest expense (206,000 ) (222,000 ) (988,000 ) (943,000 )
Gain (loss) on sale of property and equipment (19,000 ) 21,000 (29,000 )
(249,000 ) (174,000 ) (947,000 ) (861,000 )
Income (loss) before income taxes 128,000 (533,000 ) 291,000 (607,000 )
Income taxes/(benefit) 92,000 (328,000 ) 392,000 (404,000 )
Net income (loss) $ 36,000 $ (205,000 ) $ (101,000 ) $ (203,000 )
Net income (loss) per share:
Basic $ 0.01 $ (0.04 ) $ (0.02 ) $ (0.04 )
Diluted $ 0.01 $ (0.04 ) $ (0.02 ) $ (0.04 )
Weighted average common and common equivalent shares outstanding:
Basic 4,871,127 4,869,502 4,870,370 4,860,095
Diluted 4,964,775 4,869,502 4,946,674 4,860,095
Last updated: Jan 16, 2006